Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. GBD 2010 Diseases and Injuries Collaborators. Lancet 396, 1204–1222 (2020).

    Article  Google Scholar 

  2. Asrani, S. K. et al. J. Hepatol. 70, 151–171 (2019).

    Article  PubMed  Google Scholar 

  3. Zhang, X. et al. BMC Gastroenterol. 22, 484 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Riazi, K. et al. Lancet Gastroenterol. Hepatol. 7, 851–861 (2022).

    Article  PubMed  Google Scholar 

  5. Pellicoro, A. et al. Nat. Rev. Immunol. 14, 181–194 (2014).

    Article  CAS  PubMed  Google Scholar 

  6. Ginès, P. et al. Lancet 398, 1359–1376 (2021).

    Article  PubMed  Google Scholar 

  7. Karlsen, T. D. et al. Lancet 399, 61–116 (2022).

    Article  PubMed  Google Scholar 

  8. European Association for the Study of the Liver. J. Hepatol. 75, 659–689 (2021).

    Article  Google Scholar 

  9. Graupera, I. et al. BMC Public Health 22, 1385 (2022).

Download references


The LiverScreen project is funded by European Union’s Horizon2020 programme under grant agreement no. 847989.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Pere Ginès.

Ethics declarations

Competing interests

P.G. has received research funding from Gilead, Mallinckrodt, Grifols and Ferring; consulting fees from Grifols SA, Ferring Pharmaceuticals, Gilead, Intercept, Martin Pharmaceuticals, Promethera, Sequana, RallyBio and Behring. M.T. has been funded by a grant from the Novo Nordisk Foundation (DECIDE project, grant no. NNF20OC0059393), and received speaker’s fee from Echesens, Siemens Healthcare, Norgine and Tillotts Pharma and an advisory fee from GE Healthcare. R.J.dK. has received honoraria for consulting or speaking in the past 5 years from AbbVie, BMS, Echosens, Gilead, Jansen-Cilag and Norgine; fees for contract research for current trials from Echosens, GSK, Inventiva-Pharma and Jansen-Cilag; and research grants from Gilead. L.C. has received a research grant from Gilead; consulting fees from Echosens, Madrigal, MSD, Novo Nordisk, Pfizer and Sagimet; and lecture fees from Echosens and Novo Nordisk. I. Grgurević has received speaker fees from Echosens, Siemens and Roche and holds an advisory board position at General Electric. S.P. has received consulting fees from Plasma Protein Therapeutics Association and Resolution therapeutics. N.F. has received consulting fees from Intercept. All other authors report no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ginès, P., Thiele, M., Graupera, I. et al. Screening for fibrosis to diagnose liver diseases early: the LIVERSCREEN project. Nat Med 29, 774–775 (2023).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing